Changrong Ziben

NAKI Therapeutics is a biopharmaceutical company established in 2020 and based in Summit, New Jersey, focusing on the development of innovative immunotherapies for cancer treatment. The company specializes in Chimeric Antigen Receptor (CAR)-Natural Killer (NK) cell therapies, which are designed to effectively and safely eliminate cancer cells. NAKI Therapeutics re-engineers NK cells to specifically target the CD147 surface marker found on cancer cells, enhancing the potential for more effective treatment outcomes compared to traditional therapies. Through its research-driven approach, NAKI Therapeutics aims to advance the field of cancer immunotherapy and improve patient care.

Ling Siwei is a chip designer focusing on IoT communications.

Amberstone Biosciences specializes in the discovery of novel immunotherapies aimed at addressing unmet medical needs through advanced technologies and strategic collaborations. The company focuses on challenging therapeutic targets that require unique mechanisms of action, which traditional methods struggle to tackle. Amberstone employs a microfluidics-powered drug discovery platform, known as AmberFlow, to analyze single-cell functions within a customizable microenvironment. This innovative approach allows for a more precise understanding of immune responses, enabling the development of transformative therapeutic antibodies. The team's expertise in immuno-oncology and single-cell assay biology further enhances their capacity to create effective treatments, ultimately improving patient outcomes.

Eubulus is an early-stage company focusing on building a platform technology for therapeutic enhancement. The company specializes in Proteolysis- targeting chimeras (PROTACSs).

Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.

Focus-X Therapeutics is a preclinical-stage biotechnology company that specializes in the development of radiopharmaceuticals for cancer treatment. The company aims to address unmet needs in cancer diagnosis and therapy by employing a theragnostic approach, particularly targeting solid tumors with low five-year survival rates. Focus-X Therapeutics is advancing its proprietary radioligand therapy, which utilizes alpha and beta emitters to precisely disrupt cancer cell DNA. By optimizing peptide ligand vectors, the company seeks to create innovative theranostic agents that offer medical practitioners new mechanisms for treating cancer effectively.

Elgia Therapeutics is a biotechnology company focused on developing innovative treatments for chronic inflammatory and fibrotic diseases. The company employs novel approaches in drug discovery, utilizing high-throughput chemical screening and structure-based design to identify and develop small molecule inhibitors targeting specific protein pathways. By understanding the role of metabolic stress in driving inflammation and fibrosis, Elgia Therapeutics aims to create effective therapies for patients suffering from debilitating chronic conditions. Its commitment to advancing healthcare through the development of these targeted treatments positions it as a significant player in the pharmaceutical and therapeutic landscape.

Proviva Therapeutics is a pro-drug design platform for cytokines and other fusion proteins. It is committed to solving the problem of drug metabolism and the delivery of cytogenic drugs.

Shengshi Huaneng is committed to the collection, purification, and comprehensive utilization of methane-based greenhouse gases such as urban and rural agricultural and forestry biomass fermentation biogas, coal mine gas, and industrial tail gas, as well as distributed energy and other carbon emission reduction fields, to help China's carbon neutral development strategy.

ASI Semiconductor is a manufacturing company that develops and sells IC chips and related products.

Viva Biotech Holdings is a Shanghai-based company that specializes in structure-based drug discovery services for biotechnology and pharmaceutical clients worldwide. Founded in 2008, the company offers a comprehensive range of research and development services, including fragment-based drug discovery and advanced screening technologies such as affinity selection mass spectrometry and cryo-electron microscopy. Viva Biotech provides various products, including cell lines, crystal structures, GPCR proteins, and antibodies, alongside services in medicinal chemistry, in vitro pharmacology, and antibody discovery. The company operates as an integrated drug discovery platform, combining its expertise in early-stage drug research with contract development and manufacturing services for small molecule active pharmaceutical ingredients and intermediates. Its innovative approach and advanced technological platforms position Viva Biotech as a valuable partner in the global drug development landscape.

EO Company is a technology and industry innovation service platform that specializes in the large health sector. Its core offerings include health technology media, industry business conferences, and research consultations. Targeting the business end of the health industry, EO Company provides a range of online products such as industry content planning, video columns, and consulting services. The platform is designed to facilitate connections within the industry chain and offers insights backed by high market attention and an international perspective. By focusing on technological and industrial innovation, EO Company aims to support the advancement of the health sector in China.

Chinese one-stop enterprise service platform.

Onlyou offers advanced solutions and services focused on finance and taxation for large and medium-sized enterprises, as well as administrative institutions. Leveraging artificial intelligence, cloud computing, and big data technology, the company aims to simplify and enhance financial and tax management. Its intelligent tax platform delivers comprehensive financial and tax support, allowing clients to access crucial services with increased efficiency and accuracy. By combining innovative technology with extensive practical experience in the financial sector, Onlyou addresses the complex needs of its clientele in the finance and taxation landscape.

Arthrosi Therapeutics is a biotechnology company dedicated to drug discovery and development, with a specific focus on therapies for gout and chronic kidney disease. The company is engaged in clinical-stage research aimed at reducing flare-ups and tophi in gout patients. By developing innovative treatments, Arthrosi Therapeutics enables healthcare professionals to achieve significant uric acid reduction and address joint damage associated with tophi, thereby improving patient outcomes in these conditions.

Dogma Therapeutics is a biotechnology company based in the United States that specializes in developing small molecule inhibitors targeting PCSK9, a protein involved in cholesterol regulation. The firm has successfully identified orally bioavailable small molecule inhibitors that effectively lower blood lipid levels, addressing a significant challenge in the pharmaceutical industry, where previous attempts primarily relied on monoclonal antibodies. Utilizing high-resolution x-ray structures of their compounds bound to PCSK9, Dogma Therapeutics employs structure-based design to achieve high-affinity interactions. This innovative approach aims to transform the treatment landscape for cholesterol management and improve the economic viability of PCSK9-based therapies.

wanmen.org is an online education platform that provides multiple courses.